A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

2022357 citationsJournal Articlehybrid Open Access

Authors

Christine Parkinson · Addenbrooke's Hospital

Myong Cheol Lim · National Cancer Center

David M. O’Malley · The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Ana Oaknin · Vall d'Hebron Hospital Universitari

Michelle Wilson · Auckland City Hospital

Robert L. Coleman

Abstract

Rucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.

Topics & Keywords

PARP inhibition in cancer therapy Toxin Mechanisms and Immunotoxins Ovarian cancer diagnosis and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 40, Issue 34, pp. 3952-3964

DOI: 10.1200/jco.22.01003

Field-Weighted Citation Impact: 34.57